Summary
Current methods of screening for breast and colorectal cancer are limited in availability and associated with a high cost. For example, mammography equipment for breast cancer screening is particularly limited in Eastern Europe due to the expensive equipment and the required skills that a medical professional must possess. Cologaurd’s and colonoscopy’s for colorectal cancer screening are invasive and painful procedures associated with low patient compliance (50% and 37% respectively). Furthermore blood tests that have been developed to date for cancer screening have failed to demonstrate a high level of accuracy.
Todos Medical have developed a simple method for cancer screening known as TBIA (Total Biochemical Infrared Analysis). The CE-marked TBIA platform is unique being the first method using blood tests to show high sensitivity (>90%) and high specificity (>80%). It is a more cost effective and less invasive solution that is more accessible to end user and motivates increased compliance by patients. It is capable of producing results rapidly with the complete process “sample to result” taking less than 4 hours.
During phase 1, a feasibility study will be carried out, together with the planning of clinical trials in hospitals that will be performed during the innovation project, to gain the validation and bring the product to the commercialization.
Todos Medical have developed a simple method for cancer screening known as TBIA (Total Biochemical Infrared Analysis). The CE-marked TBIA platform is unique being the first method using blood tests to show high sensitivity (>90%) and high specificity (>80%). It is a more cost effective and less invasive solution that is more accessible to end user and motivates increased compliance by patients. It is capable of producing results rapidly with the complete process “sample to result” taking less than 4 hours.
During phase 1, a feasibility study will be carried out, together with the planning of clinical trials in hospitals that will be performed during the innovation project, to gain the validation and bring the product to the commercialization.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: | https://cordis.europa.eu/project/id/718491 |
Start date: | 01-02-2016 |
End date: | 31-05-2016 |
Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Current methods of screening for breast and colorectal cancer are limited in availability and associated with a high cost. For example, mammography equipment for breast cancer screening is particularly limited in Eastern Europe due to the expensive equipment and the required skills that a medical professional must possess. Cologaurd’s and colonoscopy’s for colorectal cancer screening are invasive and painful procedures associated with low patient compliance (50% and 37% respectively). Furthermore blood tests that have been developed to date for cancer screening have failed to demonstrate a high level of accuracy.Todos Medical have developed a simple method for cancer screening known as TBIA (Total Biochemical Infrared Analysis). The CE-marked TBIA platform is unique being the first method using blood tests to show high sensitivity (>90%) and high specificity (>80%). It is a more cost effective and less invasive solution that is more accessible to end user and motivates increased compliance by patients. It is capable of producing results rapidly with the complete process “sample to result” taking less than 4 hours.
During phase 1, a feasibility study will be carried out, together with the planning of clinical trials in hospitals that will be performed during the innovation project, to gain the validation and bring the product to the commercialization.
Status
CLOSEDCall topic
PHC-12-2015-1Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all